findmyKOL

Regina Dodis, D, O

Basic profile

Launchpad Central

ORCIDNone on fileNPI
RegionGreenville, NC · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Regina Dodis is an Endocrinology/Metabolic physician affiliated with Launchpad Central. OpenAlex indexes 6 publications with 344 citations (h-index 4).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
6publications

Distinct works indexed by OpenAlex.

344citations

Total citations across indexed works.

4h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
43companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1006 Wh Smith Blvd
Greenville, NC 278345194

Telephone

252-413-6683

Registry record last updated 29 Jun 2015.

View the NPPES registry record

Industry payments

43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    49.6%
    RANK Ligand Inhibitor49.5%
    Denosumab100%Prolia0%
    Part D + Part B<11 patients
    gamma-Aminobutyric Acid-ergic Agonist0.1%
    Baclofen100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    27.5%
    Insulin Analog10.3%
    Novolog Flexpen12%Tresiba Flextouch U-10011%Toujeo Solostar10%Humalog Kwikpen U-1009%Lantus Solostar9%Tresiba Flextouch U-2006%Toujeo Max Solostar6%Novolog6%Fiasp Flextouch5%Humalog5%Insulin Lispro Kwikpen U-1004%Insulin Lispro4%Fiasp3%Lyumjev3%Basaglar Kwikpen U-1003%Insulin Aspart Flexpen3%Lyumjev Kwikpen U-1002%Humalog Kwikpen U-2002%
    Part D<11 patients
    GLP-1 receptor agonist5.6%
    Ozempic69%Trulicity12%Mounjaro12%Rybelsus7%
    Part D<11 patients

    + 13 more classes in this area

  • Hormonal (systemic)

    12%
    l-Thyroxine8.7%
    Levothyroxine Sodium71%Synthroid28%Euthyrox2%
    Part D<11 patients
    Thyroid Hormone Synthesis Inhibitor2.1%
    Methimazole100%
    Part D51 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”